Compare · MGRM vs WST
MGRM vs WST
Side-by-side comparison of Monogram Technologies Inc. (MGRM) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRM and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $22.59B.
- Over the past year, MGRM is up 127.3% and WST is up 43.0% - MGRM leads by 84.3 points.
- WST has hit the wire 4 times in the past 4 weeks while MGRM has been quiet.
- WST has more recent analyst coverage (16 ratings vs 1 for MGRM).
- Company
- Monogram Technologies Inc.
- West Pharmaceutical Services Inc.
- Price
- $6.00-1.72%
- $320.02+1.78%
- Market cap
- -
- $22.59B
- 1M return
- +4.80%
- -0.60%
- 1Y return
- +127.27%
- +42.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 16
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MGRM
- SEC Form EFFECT filed by Monogram Technologies Inc.
- SEC Form EFFECT filed by Monogram Technologies Inc.
- SEC Form 15-12G filed by Monogram Technologies Inc.
- SEC Form 4 filed by Director Gray Colleen
- SEC Form 4 filed by Director Gray Colleen
- SEC Form 3 filed by new insider Gray Colleen
- SEC Form S-8 POS filed by Monogram Technologies Inc.
- SEC Form POS AM filed by Monogram Technologies Inc.
- SEC Form POS AM filed by Monogram Technologies Inc.
- SEC Form 4 filed by Director Van Kirk Richard Lee Jr
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)